BioCryst Pharmaceuticals (BCRX) Scheduled to Post Quarterly Earnings on Monday

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) is set to post its quarterly earnings results before the market opens on Monday, May 6th. Analysts expect the company to announce earnings of ($0.22) per share for the quarter. Parties that wish to register for the company's conference call can do so using this link.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last released its quarterly earnings results on Monday, February 26th. The biotechnology company reported ($0.28) EPS for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.04). The company had revenue of $93.40 million for the quarter, compared to analysts' expectations of $89.19 million. On average, analysts expect BioCryst Pharmaceuticals to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

BioCryst Pharmaceuticals Stock Up 2.6 %

NASDAQ:BCRX traded up $0.11 during mid-day trading on Monday, hitting $4.27. 3,025,282 shares of the stock traded hands, compared to its average volume of 3,296,711. BioCryst Pharmaceuticals has a 52 week low of $4.03 and a 52 week high of $9.06. The stock has a market capitalization of $881.03 million, a price-to-earnings ratio of -3.55 and a beta of 1.90. The firm's 50 day moving average is $5.07 and its two-hundred day moving average is $5.52.

Analyst Ratings Changes

Separately, Needham & Company LLC reaffirmed a "buy" rating and set a $12.00 target price on shares of BioCryst Pharmaceuticals in a research note on Wednesday, April 10th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $13.83.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.